These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 10936507

  • 1. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R.
    Immunopharmacology; 2000 Jul 20; 48(2):95-100. PubMed ID: 10936507
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT.
    J Neurol Neurosurg Psychiatry; 2002 Aug 20; 73(2):148-53. PubMed ID: 12122172
    [Abstract] [Full Text] [Related]

  • 4. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C, Gibassier J, de Seze J, Debouverie M, Moreau T, Pelletier J, Vermersch P, Edan G.
    Clin Chim Acta; 2008 May 20; 391(1-2):98-101. PubMed ID: 18249193
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.
    Herndon RM, Rudick RA, Munschauer FE, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.
    Mult Scler; 2005 Aug 20; 11(4):409-19. PubMed ID: 16042223
    [Abstract] [Full Text] [Related]

  • 7. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC.
    Neurology; 2007 Mar 27; 68(13):977-84. PubMed ID: 17389300
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis.
    Malucchi S, Sala A, Gilli F, Bottero R, Di Sapio A, Capobianco M, Bertolotto A.
    Neurology; 2004 Jun 08; 62(11):2031-7. PubMed ID: 15184610
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.
    Vartanian TK, Zamvil SS, Fox E, Sorensen PS.
    Neurology; 2004 Dec 14; 63(11 Suppl 5):S42-9. PubMed ID: 15596736
    [Abstract] [Full Text] [Related]

  • 12. A comparative study of the relative bioavailability of different interferon beta preparations.
    Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, Reindl M, Berger T.
    Neurology; 2000 Jun 13; 54(11):2055-60. PubMed ID: 10851362
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C, Tripp P, Reichartseder F, Egg R, Ehling R, Lutterotti A, Khalil M, Kuenz B, Mayringer I, Reindl M, Berger T, Deisenhammer F.
    Mult Scler; 2006 Dec 13; 12(6):731-7. PubMed ID: 17263000
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
    Antonelli G, Simeoni E, Bagnato F, Pozzilli C, Turriziani O, Tesoro R, Di Marco P, Gasperini C, Fieschi C, Dianzani F.
    J Neurol Sci; 1999 Oct 15; 168(2):131-6. PubMed ID: 10526196
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.